NewsRoom Articles - Page 67 of 154 - PsychedelicNewsWire (PNW)

ThursdayMar 03, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patent Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of…

WednesdayMar 02, 2022 2:16 pm

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Teams Up with Chopra Foundation to Foster Psychedelics Therapy Awareness

Dr. Deepak Chopra recently stated that there was an urgent need for more effective treatments in the mental health space, a statement with which Doug Drysdale, CEO of Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), agrees. Drysdale stated that he believed that the largest barrier in the advancement of the flourishing psychedelics industry was the stigmatization and misinformation concerning psychedelic compounds. He explained that many individuals who weren’t involved in the psychedelics sector knew so little about these compounds and had warped perceptions about what they could do, giving the example of a conversation he had with one scientist who…

TuesdayMar 01, 2022 2:18 pm

Study Finds Psilocybin Use Lowers Odds of Being Arrested

A new study has linked the use of psilocybin with a reduction in the likelihood of an individual engaging in criminal behavior. Psilocybin is the active compound found in hallucinogenic mushrooms. Harvard University clinical psychology PhD candidate Grant Jones, the author of the study, stated that his interest in psychedelics grew as the substances gained more attention because of their treatment potential, having demonstrated that they could be used to relieve a number of mental health conditions. Jones explained that the purpose of the research was to investigate the relationship between criminality and psychedelics using population-based survey data, because not…

MondayFeb 28, 2022 10:29 am

At-Home Ketamine Treatments for Mental Disorders Boom in US

Ketamine for the treatment of various mental health conditions, particularly depression, is growing in the United States. However, while the ease of prescription rules is fueling increases in drug offerings, some experts are concerned that this may cause a regulatory crackdown, as the long-term impact of this particular anesthetic hasn’t been well studied. Boris Heifets, an assistant professor of anesthesiology at Stanford University, explained that it would be better if the drug was slowly rolled out to better implement a much more integrated approach to mental health. Ketamine, which was once a taboo party drug, has been available in the…

MondayFeb 28, 2022 9:45 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Tackles Pandemic-era Mental Health Crises with Product R&D and Educational Efforts for the Application of Psychedelics Technology

Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needs Delic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness clinics providing ketamine treatments in the U.S.; Reality Sandwich and Meet Delic, media properties providing education on psychedelics; and DELIC Labs, a federally-authorized research facility The company’s CSO has spoken at a number of conferences on the importance of controlling the extraction production processes for…

MondayFeb 28, 2022 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005

Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005 This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea The company is excited about this finding, terming it one of the many exciting drug discoveries it looks to share in the near term Microdosing, the act of consuming a minimal dose of a psychedelic to benefit from what it offers without going through a…

FridayFeb 25, 2022 1:49 pm

Psychedelic Therapeutics Market May Receive Federal Approval Before Marijuana Does

In a recent interview, Palo Santo cofounder and partner Tim Schlidt stated that he believed that the federal legalization pathway for psychedelics was much smoother than cannabis’ approach. Palo Santo is a psychedelic investment fund, and Schildt has been working to help increase the supply of clinically effective and accessible addiction and mental health treatment solutions. This comes as psychedelic therapeutics gain more recognition in the mainstream medical space. However, there’s still concern that these treatments may have negative outcomes in the longterm. When asked about whether the psychedelic therapeutics market could in the future outpace the marijuana market, Schlidt…

ThursdayFeb 24, 2022 3:50 pm

VIU Set to Launch First Psychedelics Therapy Course in Canada

Vancouver Island University (“VIU”) plans to launch its psychedelic-assisted therapy course in September of this year. This will make it the first accredited university in Canada to offer this course for healthcare professionals, under its Faculty of Health and Human Services. Shannon Dames, the institution’s nursing professor, stated that this launch was significant because it recognized that psychedelic-assisted therapy was an advanced practice that required a unique skill set. Laura McLean, one of the program’s registrants, signed up after she tried therapy under Roots to Thrive. Roots to Thrive is a 12-week program with virtual sessions that feature guided discussions…

WednesdayFeb 23, 2022 2:31 pm

A Review of Recent Moves Made by Psychedelic Companies

A lot has happened over the past weeks in the psychedelics industry. Below, we look at some of the moves companies in this burgeoning sector have made. Last week, Core One Labs Inc. researchers at its Vocan Biotechnologies Inc. subsidiary had received positive results and would begin using its recombinant production system to produce API-Grade N-methyltryptamine, or NMT. NMT is also known as MMT, or monomethyl tryptamine, and is a DMT precursor that the company will be producing to expand its psychedelic product pipeline. The firm is currently using its proprietary recombinant production system to produce psilocybin. In a recent…

WednesdayFeb 23, 2022 10:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon Mydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds by undertaking clinical research in partnership with academics In a recent interview, company CEO Josh Bartch emphasized the need for consistent messaging to push the adoption of psychedelics among the medical community, and help assuage concerns of patients who may be wary of psychedelic treatments…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000